Alexion   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: New Haven CT United States (1992)
Status: Acquired by AstraZeneca (2020)

Organization Overview

First Clinical Trial
2002
NCT00048308
First Marketed Drug
2007
eculizumab (Soliris)
First NDA Approval
2007
eculizumab (Soliris)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Achillion, a wholly owned subsidiary of Alexion | Alexion Antibody Technologies | ALEXION PHARM | Alexion Pharmaceuticals | Alexion Pharma GmbH | Alexion Pharma Italy s.r.l.